PHARMACY

NanoGuardian announces partnership with security firm

BY Alaric DeArment

SKOKIE, Ill. Security firm Altegrity Risk International has signed on as security partner for a company developing technology to keep diverted and counterfeited drugs out of the supply chain.

NanoGuardian announced the partnership with ARI Tuesday, which it said will help deliver its Closed-Loop Protection program to manufacturers. Closed-Loop Protection works with NanoEncryption, in which a special code is imprinted onto the surface of a drug and uses a statistical modeling and randomized pharmacy auditing system to identify counterfeit and diverted drugs on pharmacy shelves.

“NanoGuardian is committed to forging relationships with best-of-class partners in our effort to protect patients and brands,” NanoGuardian EVP Dean Hart said. “We are very excited to announce another such partnership with ARI, a global leader in corporate security with significant experience in the pharmaceutical space.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Warner Chilcott, Sanofi-Aventis clarify Actonel partnership

BY Alaric DeArment

ARDEE, Ireland Warner Chilcott will take full control over the promotion, marketing and research-and-development decisions for an osteoporosis drug in the United States under an amendment to an agreement with French drug maker Sanofi-Aventis, Warner Chilcott announced Monday.

The earlier version of the agreement, for the drug Actonel (risendronate sodium), allowed Warner Chilcott to share the costs with Sanofi in the United States.

The agreement between the two companies expires at the end of 2014.

“The amendment to the collaboration agreement will enable Warner Chilcott to assume full control over the promotion and marketing of the Actonel brand in the United States,” Warner Chilcott president and CEO Roger Boissonneault said. “This will allow us to adjust our promotional plans in the U.S. as we prepare for the potential launch of the next-generation Actonel product.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA seizes drugs from Beehive Botanicals

BY Alaric DeArment

SILVER SPRING, Md. Federal government officials seized “dozens” of products from a company they said had been warned about misstating its medical benefits.

The Food and Drug Administration announced Monday that U.S. Marshals seized products including creams, capsules, tablets, gum, throat spray and shampoos from Haywood, Wis.-based Beehive Botanicals.

According to the FDA, the company misbranded the products by promoting them on its Web site as capable of preventing and curing diseases such as asthma, dermatitis, ulcers, cancer and others. The agency said that the claims meant the products were drugs and were thus subject to FDA regulation, but that Beehive had continued marketing them as medically beneficial despite not subjecting them to clinical trials.

“This seizure shows that the FDA will seek enforcement action against companies that promote therapeutic benefits of products not yet evaluated by the agency for safety and effectiveness,” FDA acting associate commissioner for regulatory affairs Michael Chappell said in a statement.

The FDA originally warned Beehive in March 2007 not to make drug claims on its Web site and products, and the company originally complied, but during inspections in September and October 2009, the agency said it found the company still was making inaccurate drug claims.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?